News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Drugs To Help Maintain Independence, Ward Off M&A Prospects: Actelion Ltd. (ALIOF.PK) CEO


6/19/2014 6:41:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Actelion Ltd. (ATLN)’s successful drug-development record has earned the Swiss company the right to stay independent after figures from a lung-medicine study beat its expectations, Chief Executive Officer Jean-Paul Clozel said.

Results from a late-stage trial of the experimental drug selexipag for pulmonary arterial hypertension were twice as good as Clozel expected, the CEO said in an interview yesterday in Basel, Switzerland. With the approval last year of Opsumit for the same disease, the Allschwil-based company has two potential blockbuster treatments for the first time.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES